Poland· PL-100000362
Xyrem
A sodium oxybate product containing natrii hydroxybutyras, registered in Poland by UCB Pharma S.A.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Sodium oxybate is registered in 14 of 19 countries.
Countries holding a registration under ATC N07XX04 (sodium oxybate), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Sodium oxybate · ATC N07XX04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Natrii hydroxybutyras
- Manufacturer
- UCB Pharma S.A.
- Country
- Poland (PL)
- ATC code
- N07XX04
- ATC class
- Sodium oxybate
- Defined daily dose
- 7.5 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990022502
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
65 interactions on record for sodium oxybate.
Graded by severity as the source publishes them — 54 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sodium oxybate · interactions on record
65 records
- 54 severe
- 11 moderate
Most severe, free to view
- MetoclopramideA03FA01severe
- ThiethylperazinA04AB03severe
- DiphenhydraminA04AB05severe
- DronabinolA04AD10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sodium oxybate in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/28ac0aee-3b8c-4751-82e9-28f0b22dcca2 GET /v1/drugs/28ac0aee-3b8c-4751-82e9-28f0b22dcca2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór doustny",
"source": "urpl",
"strength": "500 mg/ml",
"packaging": "05909990022502 ¦ Rpz ¦ EU/1/05/312/001 ¦ 34656\n1 butelka 240 ml",
"substance": "Natrii hydroxybutyras 500 mg/ml",
"common_name": "Natrii hydroxybutyras",
"pl_product_id": "100000362",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about sodium oxybate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.